ZINZINO AB (PUBL.): INTERIM REPORT FIRST QUARTER 2025
GOTHENBURG, Sweden, May 20, 2025 /PRNewswire/ --
STRONG SALES GROWTH AND INCREASED EARNINGS IN THE FIRST QUARTER
Revenues in the first quarter of 2025 amounted to SEK 723.7 (454.5) million, corresponding to 59% (15%) growth compared to the corresponding period last year. In local currencies, revenues for the first quarter increased by 60% compared to the corresponding period last year. EBITDA increased to SEK 78.8 (51.7) million and the EBITDA margin amounted to 10.9% (11.4%). During the quarter, the acquisition of Zurvita's assets with associated distributor and customer database was completed. The acquisition consolidates Zinzino's position in North America and adds further growth in the region. In addition, New Zealand was launched as an official market during the quarter. After the end of the quarter, the assets of the US/UK based direct sales company Valentus Global was acquired in order to add increased distribution power in Europe.
JANUARY-MARCH
- Total revenue amounted to SEK 723.7 (454.5) million, corresponding to a growth of 59% (15%)- Gross profit amounted to SEK 223.6 (160.9) million and the gross profit margin was 30.9% (35.4%)- EBITDA amounted to SEK 78.8 (51.7) million and the EBITDA margin was 10.9% (11.4%)- Cash flow from operating activities totalled SEK 21.1 (-1.7) million- Zinzino's Board of Directors proposes a dividend to shareholders of SEK 4.00 (3.00) per share for the financial year 2024, corresponding to a total of SEK 143.1 (102.7) million
Link to the report:https://www.zinzino.com/site/SE/sv-SE/om-oss/investerare/
For more information, please contact:Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, dag@zinzino.comFredrik Nielsen CFO Zinzino +46 (0) 707 900 174, fredrik.nielsen@zinzino.com
Images for free publication:marketing@zinzino.com
Certified Adviser: DNB Carnegie Investment Bank AB
Zinzino AB (publ.) is obliged to publish this information in compliance with current EU regulations governing market abuse. The information was provided by the above contact person for publication at 10:00 CEST on 20 May 2025.
Zinzino is a global direct selling company from Scandinavia specialising in test-based, personalised supplements and scientific skincare. It is a public limited company with shares listed on Nasdaq First North Premier Growth Market. The company's scientifically proven supplements are available in more than 100 markets worldwide. Zinzino has acquired all the assets of the US health and wellness companies Zurvita and Xelliss. The company is part-owner of the Cypriot olive oil manufacturer Cleanthi Alpha-Olenic LTD and owns the Swiss biotech skincare brand HANZZ+HEIDII, as well as the Norwegian research and production units BioActive Foods AS and Faun Pharma AS. The company is headquartered in Gothenburg, Sweden, with additional offices in Europe, Asia and Australia.
View original content:https://www.prnewswire.com/news-releases/zinzino-ab-publ-interim-report-first-quarter-2025-302460666.html
SOURCE Zinzino
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Nucleus Genomics Launches Nucleus Embryo, Genetic Optimization Software Alongside Partnership with Genomic Prediction
Parents pursuing IVF now have a new level of choice to empower their family planning NEW YORK, June 4, 2025 /PRNewswire/ -- With U.S. birthrates plummeting and IVF on the rise, Nucleus Genomics today launched Nucleus Embryo, the first genetic optimization software that lets parents see and understand a complete genetic profile to select an embryo. "Before there's a heartbeat, there's DNA," said Kian Sadeghi, founder and CEO of Nucleus. "One file containing DNA and genetic markers can tell you more about your baby's future than any other test a doctor could possibly run at this stage. Most clinics stop at whether an embryo will develop. For many parents, that's not enough. Patients have long asked for more transparency from clinics, and Nucleus Embryo is an important step toward complete data ownership for parents planning their families." The software enables parents to analyze and compare up to 20 embryos across over 900 hereditary conditions and 40 additional analyses beyond basic viability, spanning cancers, chronic conditions, appearance, cognitive ability, mental health, and more. To widen access to the software, Nucleus will partner with Genomic Prediction, the first company to offer genome-wide screening on embryos. The partnership sets a new standard in genetic medicine, continuing Genomic Prediction's decade-long history of giving hopeful parents the best possible chance of implanting healthy embryos. The company's analyses focus on hereditary conditions, acting as the first line of defense against chronic and rare diseases. "As an organization, we are committed to supporting patients' rights to their DNA and any information that can aid in their family-building journey," said Kelly Ketterson, CEO of Genomic Prediction. "We have a legacy of innovation aimed at providing patients with access to the best scientific resources. Our partnership with Nucleus opens access to information our patients have requested and allows us to uphold our commitment to this legacy." Nucleus' partnership with Genomic Prediction reflects a growing shift in how parents think about genetics as a tool to give children the best possible start in life. A wide-ranging study of Americans found the majority accepted the use of genetic technology to choose embryos based on health and personality traits. Four in 10 parents would use genetic optimization as another tool to understand their future child's cognitive abilities. Most women undergo three to six IVF cycles before successfully having a baby, with each cycle costing up to $25,000. Many embryos are unviable within days of being fertilized, leaving parents with few to choose from. Facing high stakes, clinicians often recommend genetic testing to optimize a couple's chances of a healthy pregnancy. But these tests typically stop at a select number of hereditary conditions and chromosome count. Now, advanced genetic analysis from Nucleus gives parents a new window into the health and well-being of their future child. Nucleus Embryo provides a comprehensive genetic profile for each embryo, encompassing hereditary genetic diseases, like cystic fibrosis and hemochromatosis, alongside genetic measures of cognitive ability, mental health, and risk for chronic diseases. Wide access to genetic insights for embryos can also help extend lifespan from the earliest stages of life. While more than half of all deaths annually in the U.S. are attributed to chronic, age-related conditions — such as Alzheimer's disease, diabetes, cancer, and heart disease — research shows embryonic selection can materially help reduce disease risk for these conditions. "We celebrate health optimization and the pursuit of longevity in every other part of life via our focus on training, supplements, and sleep," Sadeghi said. "We all know health isn't just the absence of disease. It's the ability to understand our bodies and genetic makeup to reach our full potential. Now we can apply this principle to life's inception." About Nucleus Genomics Nucleus builds software for generational health. Inspired by the loss of his cousin who died of a rare — yet preventable — genetic disease, Nucleus founder and Thiel Fellow Kian Sadeghi left an Ivy League university to build a product that could have saved her life. Our advanced DNA health test and analysis takes the guesswork out of your health, whether it's perfecting your protocols, knowing your risk for cancer, or planning for a healthy family. Follow us on social media @nucleusgenomics. About Genomic Prediction Genomic Prediction, Inc. is the frontrunner in advanced embryo screening. Our proprietary LifeView platform is state-of-the-art technology that assesses embryos for genetic health aimed at improved IVF outcomes. The LifeView Embryo Health Score Test (EHS) offers insight into the likelihood of developing conditions driven by multiple genes. It tests for significant health issues, including cardiovascular disease, diabetes mellitus, certain cancers, and mental health conditions. The EHS results are derived from the same embryo sample used in the following PGT tests: PGT-A: Identifies chromosome abnormalities in embryos. PGT-A+: Pinpoints the origin (paternal, maternal, or embryonic) of chromosome abnormalities. PGT-M: Decreases the chances of passing on monogenic (single-gene) conditions. PGT-SR: Detects chromosome abnormalities and structural imbalances, providing clarity between normal and balanced chromosomes. View original content to download multimedia: SOURCE Nucleus
Yahoo
3 hours ago
- Yahoo
After its data was wiped, KiranaPro's co-founder cannot rule out an external hack
Indian grocery delivery startup KiranaPro's recent data loss story has more holes than Swiss cheese, as the startup remains unclear whether the incident was an internal breach or an external hack. Last week, the Bengaluru-based startup discovered that it could not access its back-end servers and that all its data, including its app code, had been deleted from GitHub. The startup on Friday blamed a former employee for the breach. However, in an interview, KiranaPro co-founder and CEO Deepak Ravindran conceded that the company had not deactivated the employee's account after they departed the company and cannot rule out the possibility of subsequent malicious misuse of their account. "If we go deeper, we have to do a real forensic investigation. We are going to talk [about] this with our board, the investors, and we are going to get a formal opinion on that also with our legal advisers," Ravindran told TechCrunch. Earlier on Friday, Ravindran claimed in a post on X that the incident that affected its data was an internal breach. "After careful investigation, we conclude that this was not a hack. No external party penetrated our ordering or payment systems, exploited vulnerabilities, or bypassed security protocols," he wrote. The co-founder also explicitly shared a screenshot of a LinkedIn profile of one of KiranaPro's former employees on X on Thursday, alleging that they had deleted the startup's code. (TechCrunch is not sharing the post's link, as the startup has yet to offer concrete proof supporting its position.) "[T]his was an internal data breach. Specifically, it was the result of actions taken by a trusted internal employee who had legitimate access to our systems," the co-founder wrote in his post on Friday. "This individual intentionally deleted critical server logs while they were being tested and/or edited, an action that goes directly against our policies, our principles, and the trust we place in our team." When TechCrunch asked if KiranaPro could rule out whether any third party had maliciously gained access to the former employee's account, Ravindran could not. "We have to do a complete forensic check on the company. We have to do the entire IP scan. We have to look at where the tracks happened. We have to check the computers, MacBooks, and whatever is used. Everything has to be done. Then we have to spend money … so, that's why we decided not to," he told TechCrunch. Then what was the basis of Ravindran's allegation? It was a GitHub response, a copy of which he shared with TechCrunch. The response included a username, which Ravindran said was associated with the former employee. "All we have is the emails that we got from GitHub, stating that [the former employee's username] as an individual is the one who deleted the account. We haven't done the investigation further," Ravindran told TechCrunch. Launched in late 2024, KiranaPro operates as a buyer app on the Indian government's Open Network for Digital Commerce. The startup allows more than 55,000 customers in 50 cities to purchase groceries from their local shops and nearby supermarkets using its voice-based interface. The company also supports local language inputs, including English, Hindi, Malayalam, and Tamil. Ravindran stated that they decided to call out the former employee based on the company's "belief system," as they claim the former employee deleted the data after their sudden termination. However, the startup said it is not aware if there were enough protections on the former employee's devices, such as multi-factor authentication, to restrict malicious third-party access, like malware. The company confirmed it did not remove the employee's access to its data and GitHub account following his departure. "Employee offboarding was not being handled properly because there was no full-time HR," KiranaPro's chief technology officer, Saurav Kumar, confirmed to TechCrunch. Alongside its code saved in GitHub, KiranaPro also lost access to its Amazon Web Services (AWS) account, which included its customer data and their transaction details. Ravindran told TechCrunch that the GitHub data was restored after getting its backup from one of their employees. The startup also regained access to its AWS account along with its customer data. Both the co-founder and CTO said the AWS account was protected by multi-factor authentication, but neither could say how the account was accessed, as nobody else had physical access to Ravindran's phone, which generates the multi-factor code. Nonetheless, Ravindran claimed that the customer data stored in the AWS cloud remained intact and was not accessed by any third parties, nor was it downloaded by the former employee in question. "Because if that is the case, I will get its notification on email or anything [sic]," he said. That said, Ravindran stated that the startup has enough evidence to file a formal complaint with the police, but said that its investigation is ongoing. The startup has also not fully paid its current employees, the company's co-founder confirmed, soon after the company raised a seed round of ₹100 million Indian rupees (about $1.2 million), which Ravindran said has yet to be fully wired. The startup counts Blume Ventures, Unpopular Ventures, and Turbostart among its institutional venture backers, as well as Olympic medalist PV Sindhu and Boston Consulting Group managing director Vikas Taneja among its angel investors. It has 15 employees located in Bengaluru and Kerala. Sign in to access your portfolio
Yahoo
3 hours ago
- Yahoo
The British Medical Journal Publishes Study Results on Sacituzumab Tirumotecan for Previously Treated EGFR-Mutant Advanced NSCLC
CHENGDU, China, June 6, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", today announced that results from its registrational study (OptiTROP-Lung03) evaluating sacituzumab tirumotecan (sac-TMT) versus docetaxel in patients with previously treated advanced EGFR-mutant non-small cell lung cancer (NSCLC) have been published in The British Medical Journal (impact factor: 93.6). These data were also presented as an oral presentation in the Lung Cancer—Non–Small Cell Metastatic session (Abstract #8507) at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Based on the encouraging data from this study, sac-TMT was approved for marketing by the National Medical Products Administration (NMPA) for the treatment of adult patients with epidermal growth factor receptor (EGFR) mutant-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-tyrosine kinase inhibitor (TKI) therapy and platinum-based chemotherapy in March 2025. This marks the first global approval of a TROP2 ADC for a lung cancer indication. The published results are based on OptiTROP-Lung03, an open-label, randomized, multicenter registrational study evaluating the efficacy and safety profile of sac-TMT monotherapy versus docetaxel for the treatment of patients with locally advanced or metastatic EGFR-mutant NSCLC who have failed after treatment with an EGFR-TKI and platinum-based chemotherapy. A total of 137 patients with advanced EGFR-mutant NSCLC who had progressed after EGFR-TKI and platinum-based chemotherapy were randomized (2:1) to receive sac-TMT (5 mg/kg once every 2 weeks) or docetaxel (75 mg/m2 once every 3 weeks) until disease progression, intolerable toxicity or other reason for discontinuation, with a median follow-up time of 12.2 months (Data cutoff date: December 31, 2024). Sac-TMT achieved statistically significant and clinically meaningful outcomes compared to docetaxel: Confirmed objective response rate (ORR) (As assessed by blinded independent review committee (BIRC): 45% (95% CI, 35-56) vs 16% (95% CI, 7-30). Median progression-free survival (PFS) (As assessed by BIRC: 6.9 months [sac-TMT; 95% CI, 5.4-8.2] vs 2.8 months [docetaxel; 95% CI, 1.6-4.1], hazard ratio (HR)= 0.30 [range, 0.20 -0.46], one-sided p<0.0001; as assessed by investigator (INV): 7.9 months [sac-TMT; 95% CI, 6.2-9.5] vs 2.8 months [docetaxel; 95% CI, 1.5-3.8], HR=0.23 [95% CI, 0.15-0.36], one-sided p<0.0001). With 36.4% of patients in docetaxel group crossing over to receive sac-TMT, median overall survival (OS) was not reached (NR) for both groups (HR=0.49; 95% CI, 0.27-0.88; one-sided p=0.007). The median OS analysed by pre-specified rank-preserving structural failure time (RPSFT) model adjusted for crossover was 9.3 months for docetaxel and NR for sac-TMT (HR=0.36; 95% CI, 0.20-0.66). Efficacy benefit favored patients with sac-TMT over docetaxel across all pre-specified subgroups, including prior EGFR-TKI therapy, brain metastases, EGFR mutation type, etc. Grade ≥ 3 treatment-related adverse events (TRAEs) occurred in 56.0% of patients in sac-TMT group vs 71.7% in docetaxel group. The results demonstrated that sac-TMT monotherapy achieved statistically significant and clinically meaningful improvements in objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) compared to docetaxel, with a manageable safety profile. Sac-TMT is being extensively studied in the NSCLC field. Covering treatment settings from later-line therapy to early-stage postoperative adjuvant therapy, including both monotherapy and combination regimens. Currently, five company-led registrational clinical studies for sac-TMT in NSCLC are underway in China. Meanwhile, Merck Sharp & Dohme（the tradename of Merck & Co., Inc., Rahway, NJ, USA）is also conducting five global Phase III clinical trials of sac-TMT for NSCLC in regions where it has exclusive rights. Professor Li Zhang, National Lead Principal Investigator, Medical Oncologist and Deputy Director of the Lung Cancer Research Centre at Sun Yat-Sen University, stated: "EGFR mutation is the most common driver alteration in NSCLC. The prevalence of EGFR mutations reaches 28.2% among NSCLC patients in China. Although third-generation EGFR-TKIs have become the standard of care for advanced EGFR-mutant NSCLC and may significantly improve PFS, acquired resistance remains inevitable. Combining EGFR-TKIs with chemotherapy can offer additional survival benefits to some patients, but this approach is limited by safety concerns and may compromise future treatment options, posing significant clinical challenges. The publication of the OptiTROP-Lung03 study in the British Medical Journal marks a major milestone—not only highlighting international recognition of this study outcomes in lung cancer, but also demonstrating the global competitiveness of sac-TMT as a novel TROP2 ADC." Dr. Michael Ge, CEO of Kelun-Biotech, commented: "We are thrilled to see the OptiTROP-Lung03 study published in a top-tier journal. Currently, EGFR-TKIs and chemotherapy remain the standard of care for patients with EGFR-mutant advanced NSCLC, but the challenge of increasing efficacy with manageable tolerability. The results from OptiTROP-Lung03 highlight significant survival benefits with manageable safety profile and suggest that sac-TMT could emerge as a new standard of care for this population. We remain committed to working with our partners to establish sac-TMT as a new standard of care for this patient population and improve outcomes for lung cancer patients worldwide." Registrational Study Led by Kelun-Biotech OptiTROP-Lung03: Sac-TMT monotherapy versus docetaxel for locally advanced or metastatic EGFR-mutant NSCLC after treatment failure with EGFR-TKI and platinum-containing chemotherapy； OptiTROP-Lung04: Sac-TMT monotherapy versus pemetrexed in combination with platinum for locally advanced or metastatic non-squamous NSCLC with EGFR mutations that have failed EGFR-TKI therapy； OptiTROP-Lung05: Sac-TMT combined with pembrolizumab versus chemotherapy combined with pembrolizumab for first-line treatment of PD-L1-positive locally advanced or metastatic NSCLC; OptiTROP-Lung06: Sac-TMT combined with pembrolizumab versus chemotherapy combined with pembrolizumab for the first-line treatment of PD-L1-negative locally advanced or metastatic non-squamous NSCLC; OptiTROP-Lung07: First-line treatment of locally advanced or metastatic NSCLC with EGFR mutations by sac-TMT in combination with ositinib. Registrational Study Led by MSD NSCLC not achieving a pCR after neoadjuvant therapy followed by surgery. NSCLC expressing PD-L1 >50% pre-treated NSCLC with EGFR mutations or other genomic alterations EGFR-mutated, advanced non-squ NSCLC progressed on prior EGFR-TK metastatic sg NSCLC About sac-TMT Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, BC, gastric cancer (GC), gynecological tumors, among others. Sac-TMT is developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase I inhibitor with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells. In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc., Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (includes Mainland China, Hong Kong, Macao, and Taiwan). To date, two indications for sac-TMT have been approved and marketed in China for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting) based on the OptiTROP-Breast01 study and EGFR mutation-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy based on the OptiTROP-Lung03 study. Sac-TMT became the first domestic ADC with global intellectual property rights to be fully approved for marketing. It is also the world's first TROP2 ADC to be approved for marketing in a lung cancer indication. In addition, two new indication applications for sac-TMT for the treatment of adult patients with EGFR-mutant locally advanced or metastatic NSCLC who progressed after treatment with EGFR-TKI therapy and with unresectable locally advanced, metastatic hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) BC who have received prior endocrine therapy and other systemic treatments in the advanced or metastatic setting were accepted by the National Medical Products Administration (NMPA), and were reviewed via the priority review and approval process. As of today, the Company has initiated 8 registrational clinical studies in China. MSD has initiated 14 ongoing Phase 3 global clinical studies of sac-TMT as a monotherapy or with pembrolizumab or other agents for several types of cancer. These studies are sponsored and led by MSD. About Kelun-Biotech Kelun-Biotech（ a holding subsidiary of Kelun Pharmaceutical ( which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. The company focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. The Company is committed to becoming a leading global enterprise in the field of innovative drugs. At present, the Company has more than 30 ongoing key innovative drug projects, of which 3 projects have been approved for marketing, 1 project is in the NDA stage, and more than 10 projects are in the clinical stage. The company has established one of the world's leading proprietary ADC platforms, OptiDC™, and has 1 ADC project approved for marketing, 1 ADC project in NDA stage, and multiple ADC and novel coupled drug products in clinical or preclinical research stage. For more information, please visit Media: klbio_pr@ View original content to download multimedia: SOURCE Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
